Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MDH1 | P40925 | 1/20 | 0.39 |
| ▸ | MDH2 | P40926 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 2/20 | 0.36 |
| ▸ | CES1 | P23141 | 2/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20907878 | 1.00 | PTPN1 (0.41) | PTPN1MEN1KMT2AMDH1MDH2 | |
| SCHEMBL21148968 | 0.87 | MEN1 (0.41) | PTPN1MEN1KMT2ALMNAHTT | |
| SCHEMBL28890357 | 0.87 | MEN1 (0.41) | PTPN1MEN1KMT2ALMNAHTT | |
| SCHEMBL20907565 | 0.86 | KMT2A (0.40) | PTPN1MEN1KMT2ALMNAHTT | |
| SCHEMBL20908058 | 0.86 | KMT2A (0.40) | PTPN1MEN1KMT2ALMNAHTT | |
| SCHEMBL20907601 | 0.82 | MEN1 (0.38) | PTPN1MEN1KMT2ALMNAHTT | |
| SCHEMBL21150257 | 0.82 | MEN1 (0.38) | PTPN1MEN1KMT2ALMNAHTT | |
| SCHEMBL20907868 | 0.82 | EPHX2 (0.38) | PTPN1MEN1KMT2AALDH1A1KIF11 | |
| SCHEMBL28889780 | 0.82 | EPHX2 (0.38) | PTPN1MEN1KMT2AALDH1A1KIF11 | |
| SCHEMBL20907785 | 0.81 | PTPN1 (0.40) | PTPN1MEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | PTPN1 3199/4885MEN1 2814/4885KMT2A 1556/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | PTPN1 3909/4885MEN1 463/4885KMT2A 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.